- Abstracts not accepted for presentation will not be eligible for publication either in print or online.
|
- The nonrefundable $60 administrative fee will apply.
|
- Sponsorship must be attained from an ASCO Full Member if the author is not an ASCO member.
|
- All conflict of interest policies apply.
|
- Abstracts will be judged solely on the basis of the information in the submitted abstract
|
- Abstracts should be organized according to two sections, identified by the following headers (in bold):
|
| |
Background |
| |
> Scientific background/rationale for the trial. |
| |
> Preclinical and/or earlier-phase clinical data that has already been publically presented or published may be included with references. The Trials in Progress abstract should not be used to present preclinical or earlier-phase clinical data for the first time. |
| |
> Correlative studies of particular interest |
| |
Methods |
| |
> Trial design and statistical methods, highlighting any novel aspects of the design |
| |
> Treatment or intervention planned |
| |
> Major eligibility criteria, highlighting unusual aspects |
| |
> Current enrollment without providing results or endpoints |
| |
|
o Enrollment must have already begun or have been completed with no data analysis available. |
| |
|
o Phase I studies may say, “Cohorts 1 and 2 have been completed without DLT. Enrollment to cohort 3 began in January 2012.” |
| |
|
o Phase II studies may report, “8 of planned 32 patients have been enrolled” or “Prespecified activity goal for the first stage of accrual was met; second stage accrual began in January 2012.” |
| |
|
o Phase III trials may report, “The DMC last reviewed the trial in December 2011 and suggested that the trial continue as planned.” |
> Clinical trial registry number (required)
|
- Do not exceed 2,000 characters (approximately 300 to 350 words) for the total of your abstract title and body. The character count does NOT include spaces or authors.
|
- List no more than 20 individual authors for each abstract. In addition to the 20 authors, an authoring group may also be listed to indicate the remaining authors. Ensure that all coauthors meet the definition of authorship as stated by the International Committee of Medical Journal Editors in the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals.”
|
- The title should objectively describe the study. ASCO reserves the right to edit conclusive titles.
|
- Do not include any preliminary data including toxicity, response rate, PK, or correlative analyses. NOTE: Abstracts including results or preliminary data will be rejected without further review.
|
- Do not use proprietary drug names or the names of drug manufacturers in the title or body of the abstract. If necessary, you may include the proprietary drug name in parentheses directly after the generic name on first use in the body of the abstract. ASCO reserves the right to replace proprietary names with generic names to adhere to this requirement.
|
- Do not include any information about pricing, fees, or reimbursement related to trial participation.
|
- Place abbreviations in parentheses immediately after the first mention of a term or phrase; the abbreviation can then be used throughout the abstract. Take particular care to identify complex chemotherapy regimens accurately.
|